Shanghai Kehua Bio-engineering (002022.SZ): The hepatitis C virus (HCV) nucleic acid detection kit (PCR-fluorescence method) has obtained a medical device registration certificate.
Kehua Bio (002022.SZ) announced that its subsidiary, Suzhou Tianlong Biotechnology Co., Ltd., has recently...
Shanghai Kehua Bio-engineering (002022.SZ) announced that its holding subsidiary, Suzhou Tianlong Bio-technology Co., Ltd., has received a medical device registration certificate (in vitro diagnostic reagent) issued by the National Medical Products Administration. The product involved is the "Hepatitis C Virus (HCV) Nucleic Acid Detection Kit (PCR-fluorescence method)". This product is used for quantitatively detecting Hepatitis C Virus nucleic acid (RNA) in human serum or plasma samples.
Related Articles
Caitong: The demand for monomers of succinylamide is expected to grow vigorously, and enterprises within the supply chain of multinational pharmaceutical companies are likely to benefit.
The Triple Play of Performance, Efficiency, and Strategy: WuXi AppTec's (02359) CRDMO model will fully bloom in Q3 2025.
GF SEC: Stable electricity and coal prices are expected to rise, focusing on improving the performance of thermal power and water resources.
Caitong: The demand for monomers of succinylamide is expected to grow vigorously, and enterprises within the supply chain of multinational pharmaceutical companies are likely to benefit.
The Triple Play of Performance, Efficiency, and Strategy: WuXi AppTec's (02359) CRDMO model will fully bloom in Q3 2025.
GF SEC: Stable electricity and coal prices are expected to rise, focusing on improving the performance of thermal power and water resources.
RECOMMEND
Why European Automakers Are Opposing Dutch Sanctions
20/10/2025
Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025
Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025
